Maple Securities Usa Inc adds Gilead Sciences (GILD) to its portfolio

Gilead Sciences (GILD) : Maple Securities Usa Inc added new position in Gilead Sciences during the most recent quarter end. The investment management firm now holds 10,196 shares of Gilead Sciences which is valued at $874,307 , the company said in a statement filed on Jul 13, 2016 with the SEC.Gilead Sciences makes up approximately 0.12% of Maple Securities Usa Inc’s portfolio.

Other Hedge Funds, Including , Capstone Asset Management Co reduced its stake in GILD by selling 1,189 shares or 0.95% in the most recent quarter. The Hedge Fund company now holds 123,679 shares of GILD which is valued at $10,605,474. Gilead Sciences makes up approx 0.31% of Capstone Asset Management Co’s portfolio. Nepsis Capital Management sold out all of its stake in GILD during the most recent quarter. The investment firm sold 36,308 shares of GILD which is valued $3,113,411.Lau Associates reduced its stake in GILD by selling 800 shares or 2.72% in the most recent quarter. The Hedge Fund company now holds 28,600 shares of GILD which is valued at $2,475,330. Gilead Sciences makes up approx 2.57% of Lau Associates’s portfolio.Daiwa Sb Investments Ltd. reduced its stake in GILD by selling 24,540 shares or 94.71% in the most recent quarter. The Hedge Fund company now holds 1,370 shares of GILD which is valued at $118,574. Gilead Sciences makes up approx 0.03% of Daiwa Sb Investments Ltd.’s portfolio.Curian Capital reduced its stake in GILD by selling 94,860 shares or 64.89% in the most recent quarter. The Hedge Fund company now holds 51,336 shares of GILD which is valued at $4,443,131. Gilead Sciences makes up approx 0.32% of Curian Capital’s portfolio.

Gilead Sciences opened for trading at $86.94 and hit $87.34 on the upside on Monday, eventually ending the session at $86.93, with a gain of 0.30% or 0.26 points. The heightened volatility saw the trading volume jump to 67,88,252 shares. Company has a market cap of $115,775 M.

On the company’s financial health, Gilead Sciences reported $3.03 EPS for the quarter, missing the analyst consensus estimate by $ -0.10 based on the information available during the earnings call on Apr 28, 2016. Analyst had a consensus of $3.13. The company had revenue of $7794.00 million for the quarter, compared to analysts expectations of $8065.42 million. The company’s revenue was up 2.6% compared to the same quarter last year. During the same quarter in the previous year, the company posted $2.94 EPS.

Many Wall Street Analysts have commented on Gilead Sciences. Gabelli & Co Initiated Gilead Sciences on Jun 1, 2016 to “Buy”, Price Target of the shares are set at $109.Gilead Sciences was Downgraded by Maxim Group to ” Hold” on Apr 29, 2016. Shares were Reiterated by UBS on Apr 29, 2016 to “Buy” and Lowered the Price Target to $ 118 from a previous price target of $130 .

Gilead Sciences Inc. (Gilead) is a research-based biopharmaceutical company that discovers develops and commercializes innovative medicines. The Company’s primary areas of focus include human immunodeficiency virus (HIV) liver diseases such as chronic hepatitis C virus (HCV) infection and chronic hepatitis B virus (HBV) infection oncology and inflammation and serious cardiovascular and respiratory conditions. The Company’s HIV products include Stribild Complera/Eviplera Atripla Truvada Viread Emtriva Tybost and Vitekta. Its Liver Diseases products include Harvoni Sovaldi Viread and Hepsera. Zydelig is the Company’s oncology product. Its Cardiovascular products include Letairis Ranexa and Lexiscan/Rapiscan. Its Respiratory products include Cayston and Tamiflu. Its other products include AmBisome and Macugen.

Leave a Reply

Gilead Sciences - Is it time to Sell?

Top Brokerage Firms are advising their investors on Gilead Sciences. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.